Pharmacosomes: The lipid-based new drug delivery system

Expert Opinion on Drug Delivery

Volumn 6, Issue 6, 2009, Pages 599-612

  Semalty, Ajay ^a   Semalty, Mona ^a   Rawat, Balwant Singh ^a   Singh, Devendra ^a   Rawat, M S M ^a  

^a H N B GARHWAL UNIVERSITY   (India)

Author keywords

Bioavailability; Non steroidal anti inflammatory drugs; Pharmacosome; Phospholipid complex

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CARDIOLIPIN; CARDIOVASCULAR AGENT; CURCUMIN; DICLOFENAC; GLYCOLIPID; HERBACEOUS AGENT; HYALURONIC ACID; HYDROGEN; INSULIN; LIPID; NARINGENIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; PHARMACOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PROTEIN; QUERCETIN; SALCATONIN; SIGMA 2 OPIATE RECEPTOR; SILIBININ; SIRAMESINE; SOLVENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG LIPID INTERACTION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SOLUBILITY; FOURIER TRANSFORMATION; GASTROINTESTINAL TOXICITY; HUMAN; INFRARED SPECTROSCOPY; MEMBRANE FLUIDITY; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MOLECULAR STRUCTURE; PHOSPHOLIPIDS;

EID: 67649211218     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902967607     Document Type: Review

References (54)

1. Mukherjee PK, Maiti K, Kumar V, et al. Value added drug delivery systems with botanicals: approach for dosage development from natural resources. Pharm Rev 2007;6:57-60
2. Samuni A, Chong P, Barenholz LGY, et al. Physical and chemical modifications of adriamycirdron complex by phospholipid bilayers. Cancer Res 1986;46:594-599 (Pubitemid 16145407)
3. Tanhuanpaa K, Cheng KH, Anttonen K, et al. Characteristics of pyrene phospholipid/g-cyclodextrin complex. Biophys J 2001;81(9):1501-1510
4. Bombardelli E, Spelta M. Phospholipid-polyphenol complexes: a new concept in skin care ingredients. Cosm Toil 1991;106(3):69-76
5. Vaizoglu O, Speiser PP. Pharmacosomes: a novel drug delivery system. Acta Pharm Suec 1986;23:163-172 • Pioneer work on pharmacosomes.
6. Biju SS, Talegaonkar S, Mishra PR, et al. Vesicular systems: an overview. Indian J Pharm Sci 2006;68:141-153 (Pubitemid 43904228)
7. Kozubek A, Gubernator J, Przeworska E, et al. Liposomal drug delivery-a novel approach: PLARosomes. Acta Biochim Pol 2000;47:639-649
8. Goyal P, Goyal K. Liposomal drug delivery systems: clinical applications. Acta Pharm 2005;55:1-25 (Pubitemid 40562616)
9. Semalty A, Semalty M, Singh R, et al. Phytosome in herbal drug delivery: a review. Indian Drugs 2006;43:937-946
10. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. Nutr Rev 1994;52:327-339 (Pubitemid 24349550)
11. Lieber CS, De Carl LM, Mak KM. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatol 1990;12:1390-1398
12. Lieber CS, Leo MA, Aleynik SI. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcohol Clin Exp Res 1997;21:375-379 (Pubitemid 27176292)
13. Kosina F, Budka K, Kolouch Z. Essential cholinephospholipids in the treatment of virus hepatitis. Cas Lek Cesk 1981;120:957-960
14. Gelenberg AJ, Dorer DJ, Wojcik JD. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149-153 (Pubitemid 20129735)
15. Growdon JH, Gelenberg AJ, Doller J. Lecithin can suppress tardive dyskinesia. N Engl J Med 1978;298:1029-1030
16. Little A, Levy R, Chuaqui-kidd P, et al. double-blind, placebo-controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatary 1985;48:736-742 (Pubitemid 15005973)
17. Hirsch MJ, Growdon JH, Wurtman RJ. Relations between dietary choline or lecithin intake, serum choline levels, and various metabolic indices. Metabolism 1978;27:953-960 (Pubitemid 8405912)
18. Hanin I, Ansell GB. LECITHIN. Technological, biological and therapeutic aspects. Plenum press, New York and London; 1987
19. Khazaeinia T, Jamali F. A comparison of gastrointestinal permeability induced by diclofenacphospholipid complex with diclofenac acid and its sodium salt. J Pharm Pharmaceut Sci 2003;6(3):352-359 (Pubitemid 38097550)
20. Semalty A, Semalty M, Rawat MSM, et al. Development and characterization of pharmacosomes of Diclofenac. 3rd Uttarakhand State Science and Technology Congress (USSTC), 2008
21. Li Y, Yang DJ, Chen SL, et al. Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods. Pharm Res 2007;25:563-577 • Describes the use of various supercritical fluid methods and their comparisons in the preparation of phospholipid complexes of a phytoconstituent.
22. Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poly-soluble active ingredients by supercritical fluid processes. Part I: micronization of neat particles. Int J Pharm 2005;288:3-10 (Pubitemid 39656449)
23. Reverchon E, Della Porta G, Failivene MG. Progress parameters and morphology in amoxicillin micro and submicro particles generation by supercritical antisolvent precipitation. J Supercrit Fluids 2000;17:239-248
24. Warwick B, Dehghani F, Foster NR, et al. Synthesis, purification, and micronization of pharmaceuticals using the gas antisolvent technique. Ind Eng Chem Res 2000;39:4571-4573
25. Shi K, Cui F, Yu Y, et al. Preparation and characterization of a novel insulin-phospholipid complex. Asian J Pharma Sci 2006;1(3-4):168-174 • This paper reported the preparation of pharmacosomes for insulin for the first time.
26. Takacs-Novak K, Jozan M, Hermecz I, et al. Lipophilicity of antibacterial fluoroquinolones. Int J Pharm 1992;79:89-96
27. Yoo HS, Park TG. Biodegradable nanoparticles containing protein-fatty acid complex for oral delivery of salmon calcitonin. J Pharm Sci 2003;93:488-495
28. Semalty M, Semalty A, Singh D, et al. Effect of purity of phospholipids in improving bioavailability performance of Aspirin-phospholipid complex, Proc. Of NCCT Annual Conference and Convention- 2008, Srinagar (Garhwal), India
29. Steve A. US patent S, 534, 499 (C1 S14-25, A61K31/70); 1996
30. Taskintuna I, Banker A S, Flores-Aguilar M, et al. Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis. Retina 1997;17:57-64 (Pubitemid 27091651)
31. Cui F, Shi K, Zhang L, et al. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 2006;114:242-250 (Pubitemid 44291843)
32. Semalty A, Semalty M, Rawat MSM. The phyto-phospholipid complexes- phytosomes: a potential therapeutic approach for herbal hepatoprotective drug delivery. Phcog Rev 2007;1(2):369-374
33. Maiti K, Mukherjee K, Gantait A, et al. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2006
34. Maiti K, Mukherjee K, Gantait A, et al. Enhanced therapeutic potential of naringenin-phospholipid complex in rats. J Pharm Pharmacol 2006;58:1227-1233 (Pubitemid 44329104)
35. Maiti K, Mukherjee K, Gantait A, et al. Enhanced therapeutic benefit of quercetin-phospholipid complex in carbon tetrachloride induced acute liver injury in rats: a comparative study. Iran J Pharmacol Ther 2005;4:84-90
36. Yanyu X, Yunmei S, Zhipeng C, et al. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm 2006;307:77-82 (Pubitemid 41773254)
37. Zhang ZR, Wang JX, Lu J. Optimization of the preparation of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine pharmacosomes using central composite design. Yao Xue Xue Bao 2001;36:456-461 (Pubitemid 33632937)
38. Lichtenberger LM, Wang ZM, Romero JJ, et al. Non steroidal anti-inflammatory drugs (NSAIDs) associate with Zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995;11:154-158
39. Goddard PJ, Kao YJ, Lichtenberger LM. Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel. Gastroenterology 1990;98:361-370 (Pubitemid 20037918)
40. Lichtenberger LM, Graziani LA, Dial EJ, et al. Role of surface-active phospholipids in gastric cytoprotection. Science 1983;219:1327-1329
41. Hills BA, Kirwood CA. Gastric mucosal barrier to hydrogen ions imparted by gastric surfactant in vitro. Gut 1992;33:1039-1041
42. Sloniany BL, Sarosiek J, Slomiany A. Gastric mucus and mucosal barrier. Dig Dis Sci 1987;5:125-145
43. Sloniany BL, Slomiany S. Role of mucus in gastric mucosal protection. J physiol Pharmacol 1991;42:141-161
44. Lichtenberger LM, Ulloa C, Romero JJ, et al. Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology 1996;111:990-995 (Pubitemid 26327601)
45. Khazaeinia T, Jamali F. Effect of drug release rate on therapeutic outcomes: formulation dependence of gastrointestinal toxicity of diclofenac in the rat. Inflammopharmacology 2004;12(1):69-80 (Pubitemid 38524363)
46. Lichtenberger LM, Ulloa C, Romero JJ, et al. Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. J Pharmacol Exp Ther 1996;277:1221-1227 (Pubitemid 27167131)
47. Garcia M, Paua DASC, Oliveira D, et al. Transdermal delivery of ketoprofen: the influence of drugdioleylphosphatidylcholine interactions. Pharm Res 2006;23(8):1776-1785 (Pubitemid 44200541)
48. Yue PF, Yuan HL, Xie H, et al. Preparation, characterization, and bioavailability of ursodeoxycholic acid-phospholipid complex in vivo. Drug Dev Ind Pharm 2008;34(7):708-718 (Pubitemid 351965485)
49. Parry MJ, Alakoskela JM, Khandelia H, et al. High-affinity small molecule-phospholipid complex formation: binding of siramesine to phosphatidic acid. J Am Chem Soc 2008;130(39):12953-12960
50. Kaufmann J, Mohle K, Hofmann HJ, et al. Molecular dynamics study of hyaluronic acid in water. J Mol Struct 1998;422:109-121 (Pubitemid 128388167)
51. Ling PX. Hyaluronan. Beijing: Zhongguo Qinggongye Chubanshe 2000:122-134
52. Yamamoto H. Antiaging and cosmetic effects of dietary hyaluronic acid (extracellular matrix extract). New Food Ind 1998;40:33-41
53. Cao D, Qiu AY, Wang XG. The structure, nature, function and researching situation of phospholipids. Liangshi yu Youzhi 2004;5:3-7
54. Huang SL, Ling PX, Zhang TM. Oral absorption of hyaluronic acid and phospholipids complexes in rat. World J Gastroenterol 2007;13:945-949 (Pubitemid 46470310)